| Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
| Q36695855 | A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease |
| Q46531729 | A comparative study of natural killer cell activity, lymphoproliferation, and cell phenotypes in nonhuman primates |
| Q36777835 | A new era in HIV vaccine development |
| Q45839333 | Absence of risk of human immunodeficiency virus (HIV) infection in recipients of hepatitis B vaccine |
| Q36423960 | Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors |
| Q40468086 | Analogie entre les rétrovirus humains lymphotropes et les rétrovirus des grands animaux. |
| Q40470626 | Analogy between lymphotropic human retroviruses and large animal retroviruses. |
| Q52844727 | Analysis of nonhuman primate peripheral blood mononuclear cells for susceptibility to HIV-1 infection and HIV coreceptor expression. |
| Q34050742 | Animal models for AIDS pathogenesis |
| Q30423656 | Animal models for HIV/AIDS research |
| Q37844065 | Animal models for development of an AIDS vaccine |
| Q40744779 | Animal models of viral sexually transmitted diseases |
| Q45157466 | Anti-IgM screening for HIV. |
| Q40815098 | Antibodies to human T-cell lymphotropic virus type III in promiscuous healthy homosexual men. Relation to immunological and clinical findings |
| Q33864057 | Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees |
| Q40551607 | Apoptosis in viral infections |
| Q37809080 | Biomedical Differences Between Human and Nonhuman Hominids: Potential Roles for Uniquely Human Aspects of Sialic Acid Biology |
| Q36376601 | Blockade of HIV-1 infection of New World monkey cells occurs primarily at the stage of virus entry |
| Q36572813 | Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells |
| Q44997483 | Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses |
| Q36832017 | Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120 |
| Q40460133 | Chronic Activation of the Immune System in HIV Infection: Contribution to T Cell Apoptosis and Vβ Selective T Cell Anergy |
| Q43000382 | Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis |
| Q46796894 | Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses |
| Q36564989 | Comparison of Class I MHC Alleles in Humans and Apes |
| Q37834099 | Coreceptor use in nonhuman primate models of HIV infection |
| Q37410532 | Current issues in developing a strategy for dealing with the acquired immunodeficiency syndrome |
| Q67921052 | Detection of anti-HIV-1 immunoglobulin M antibodies in patients with serologically proved HIV-1 infection |
| Q35884252 | Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1 |
| Q40126058 | Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. |
| Q41406431 | Distribution of the level of antibody to AIDS-associated virus (LAV) in sera from AIDS or AIDS related complex and Japanese hemophiliacs infected with AIDS-associated virus |
| Q53540186 | Effect of HTLV-III on the macromolecular synthesis in HTLV-I carrying cell line, MT-4. |
| Q37399694 | Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes |
| Q36812220 | Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. |
| Q39579134 | Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS. |
| Q40066880 | Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells |
| Q47393814 | Genetics of primate lymphomas in a baboon (Papio hamadryas) colony of Sukhumi, USSR. |
| Q36831040 | Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus |
| Q69886202 | HIV IgM antibodies in risk groups who are seronegative on ELISA testing |
| Q45840171 | HTLV-III antibody in a breeding chimpanzee not experimentally exposed to the virus |
| Q42998266 | Haemophilia, blood transfusion, and the AIDS virus |
| Q36655355 | High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. |
| Q33632668 | Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120 |
| Q33582665 | Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees |
| Q35168345 | Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. |
| Q38838864 | Humanized mice for HIV and AIDS research |
| Q34545986 | Humoral immune responses to T cell tropic retrovirus simian T lymphotropic virus type III in monkeys with experimentally induced acquired immune deficiency-like syndrome |
| Q42018824 | Immunization with Tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection |
| Q42639714 | Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1. |
| Q35855888 | Immunophenotypic characterization of the cutaneous exanthem of SIV-infected rhesus monkeys. Apposition of degenerative Langerhans cells and cytotoxic lymphocytes during the development of acquired immunodeficiency syndrome |
| Q43547367 | Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood |
| Q36807211 | In vitro susceptibility of T lymphocytes from chimpanzees (Pan troglodytes) to human herpesvirus 6 (HHV-6): a potential animal model to study the interaction between HHV-6 and human immunodeficiency virus type 1 in vivo |
| Q36515119 | In vivo platforms for analysis of HIV persistence and eradication |
| Q33810203 | Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees |
| Q33880796 | Induction of anti-HIV neutralizing antibodies by synthetic peptides |
| Q33582527 | Infection of rabbit T-cell and macrophage lines with human immunodeficiency virus |
| Q45831777 | Infection of rabbits with human immunodeficiency virus |
| Q34561070 | Insights into cellular factors that regulate HIV-1 replication in human cells |
| Q37899341 | Intracellular defenses against HIV, viral evasion and novel therapeutic approaches |
| Q35841911 | Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo |
| Q34049156 | Isolation of T-cell tropic HTLV-III-like retrovirus from macaques |
| Q33851263 | Isolation of human immunodeficiency virus-related simian immunodeficiency viruses from African green monkeys |
| Q35566030 | Kinetics and inhibition of reverse transcriptase from human and simian immunodeficiency viruses |
| Q52849599 | Laboratory and serological studies argue against possible transmission of AIDS by hepatitis B vaccine. |
| Q54984932 | Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine. |
| Q34650845 | Loss of Siglec expression on T lymphocytes during human evolution |
| Q38121073 | Macaque-tropic human immunodeficiency virus type 1: breaking out of the host restriction factors |
| Q33848331 | Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone |
| Q35914370 | Multiple restrictions of human immunodeficiency virus type 1 in feline cells |
| Q37077665 | Murine models for HIV vaccination and challenge. |
| Q34715769 | Non-human primate models for AIDS vaccine research |
| Q36793690 | Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein |
| Q39692591 | Pathogenesis of human immunodeficiency virus infection and prospects for control |
| Q44075272 | Persistent infection of baboons and Rhesus monkeys with different strains of HIV-2 |
| Q36860939 | Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome |
| Q36919244 | Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. |
| Q36783146 | Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects |
| Q45837998 | Prevalence of antibodies to human T-lymphotropic virus-III (HTLV-III) in hemophiliacs and other patients chronically substituted with blood products |
| Q45207487 | RNA-mediated transfer of cellular immunity to a synthetic env antigen of the human immunodeficiency virus (HIV-1) |
| Q39602019 | Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees |
| Q38689742 | Recent developments in the diagnosis, antiviral therapy and prevention of the acquired immune deficiency syndrome |
| Q78020776 | Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission |
| Q34903504 | Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation |
| Q36633938 | Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity |
| Q55245150 | Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. |
| Q34373003 | Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine |
| Q36651958 | Serological, biological, and molecular characterization of New Zealand white rabbits infected by intraperitoneal inoculation with cell-free human immunodeficiency virus |
| Q39742447 | Simian models of acquired immunodeficiency syndrome (AIDS): a review |
| Q43658835 | Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation |
| Q33824990 | Species-specific, postentry barriers to primate immunodeficiency virus infection |
| Q52849170 | Stages in the progression of HIV infection in chimpanzees. |
| Q41269699 | Study of the T cell receptor repertoire in viral immunodeficiency disease |
| Q36920676 | Superinfection of a chimpanzee with a second strain of human immunodeficiency virus |
| Q44246260 | Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees |
| Q42216107 | Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine |
| Q36800188 | Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees |
| Q35830294 | Syphilis superinfection activates expression of human immunodeficiency virus I in latently infected rabbits |
| Q45834058 | T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses |
| Q36920089 | T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. |
| Q34675856 | The development of an AIDS vaccine: progress and promise. |
| Q36701620 | The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo |
| Q46187118 | The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs |
| Q34282439 | The natural history of human T lymphotropic virus-III infection: the cause of AIDS. |
| Q72344523 | The significance of the pre-challenge immune status of mice for development of retrovirus-induced immunodeficiency syndrome (MAIDS) |
| Q38163930 | Treatment of the acquired immune deficiency syndrome |
| Q36117078 | Vaccination against HIV |
| Q36636293 | Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge |
| Q30417520 | Why primate models matter |